Laird Norton Wetherby Wealth Management LLC Sells 2,533 Shares of Boston Scientific Co. (NYSE:BSX)

Laird Norton Wetherby Wealth Management LLC reduced its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 9.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 25,574 shares of the medical equipment provider's stock after selling 2,533 shares during the period. Laird Norton Wetherby Wealth Management LLC's holdings in Boston Scientific were worth $2,284,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Colonial Trust Co SC increased its stake in Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 260 shares in the last quarter. TFC Financial Management Inc. increased its stake in Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 210 shares in the last quarter. West Oak Capital LLC bought a new stake in Boston Scientific in the fourth quarter valued at $29,000. Valley National Advisers Inc. grew its holdings in shares of Boston Scientific by 262.4% during the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 286 shares during the last quarter. Finally, Fairway Wealth LLC acquired a new position in shares of Boston Scientific during the fourth quarter valued at about $36,000. 89.07% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of analyst reports. Erste Group Bank upgraded shares of Boston Scientific to a "strong-buy" rating in a report on Thursday, May 8th. Needham & Company LLC lifted their price target on shares of Boston Scientific from $113.00 to $115.00 and gave the stock a "buy" rating in a report on Thursday, April 24th. Piper Sandler lifted their price target on shares of Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. UBS Group lifted their price target on shares of Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Finally, StockNews.com raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Twenty-three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $114.74.

Boston Scientific Price Performance

Shares of BSX traded up $1.14 during mid-day trading on Friday, reaching $106.00. 7,288,742 shares of the stock traded hands, compared to its average volume of 6,362,890. The firm has a fifty day moving average price of $99.18 and a 200 day moving average price of $96.74. The company has a market cap of $156.83 billion, a price-to-earnings ratio of 84.80, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a 1 year low of $71.88 and a 1 year high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The firm had revenue of $4.66 billion during the quarter, compared to analyst estimates of $4.57 billion. During the same period in the previous year, the business earned $0.56 EPS. The business's revenue for the quarter was up 20.9% on a year-over-year basis. As a group, equities research analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Insider Buying and Selling

In other Boston Scientific news, SVP Vance R. Brown sold 4,826 shares of the company's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the sale, the senior vice president now directly owns 36,193 shares in the company, valued at $3,441,592.37. This represents a 11.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP John Bradley Sorenson sold 2,657 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $104.41, for a total transaction of $277,417.37. Following the sale, the executive vice president now owns 24,294 shares of the company's stock, valued at approximately $2,536,536.54. The trade was a 9.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 265,820 shares of company stock worth $27,406,958. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.